SCHEMBL31349540

SCHEMBL31349540

O=C1Nc2ncc(F)cc2C12CCN(Cc1ccccc1)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 4/20 0.43
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
OPRK1 P41145 2/20 0.43
SIGMAR1 Q99720 4/20 0.42
CYP2D6 P10635 1/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
HIF1A Q16665 1/20 0.41
DRD2 P14416 2/20 0.41
CYP3A4 P08684 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19235263 0.80 HTR2A (0.51) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL19235383 0.77 HTR2A (0.48) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL30721771 0.77 CALCA (0.46) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL23595063 0.75 OPRL1 (0.45) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL31349435 0.74 MAP3K11 (0.42) OPRM1
SCHEMBL31349620 0.74 TSHR (0.46) OPRL1OPRM1OPRD1OPRK1CYP2D6
SCHEMBL30340781 0.73 SIGMAR1 (0.44) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL23580283 0.73 SIGMAR1 (0.44) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL4952229 0.73 OPRL1 (0.60) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL15650027 0.72 OPRL1 (0.50) OPRL1OPRM1OPRD1OPRK1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed